REMARKS

Claims 1–14 and 16 are cancelled. Claims 24, 25, and 27–31 are withdrawn. Claims 32–39 are new to this application.

In the Office Action dated August 5, 2010, the Examiner requested restriction between Group I (Claims 14–23, 25, and 26) drawn to an immunological method, Group II (Claim 24) drawing a diagnostic method for detection of a disease, and Group III (Claims 27–31) drawn to a method of screening compounds that interact with myeloperoxidase.

Applicants believe the inclusion of claim 14 in Group I is an error because claim 14 was previously cancelled. Applicants elect Group I (claims 15–23, 25, and 26) for prosecution.

The Office Action further required election of a species and a subspecies of use. As the species and subspecies listed in the Office Action at page 2 and 3 appear to correspond to non-elected claim 24 (Group II), Applicants believe the election of a species an subspecies does not pertain to Group I. However, if such election is required, Applicants elect Species A (for the detection of diseases or conditions) and "chronic or acute inflammatory disease" as the subspecies.

Application No. 10/597,636 Amendment and Response to Restriction Requirement

The Commissioner is hereby authorized to charge any additional fees which may be required in this Application to Deposit Account No. 06-1135.

Respectfully requested,

FITCH, EVEN, TABIN & FLANNERY

Date: October 28 2010

Ву

Registration No. 30,192

120 South LaSalle Street, Suite 1600

Chicago, Illinois 60603-3406

Telephone: (312) 577-7000 Facsimile: (312) 577-7007